Skip to main
SXTP
SXTP logo

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc. reported revenues of $310,000, marking a significant 20% increase sequentially and a remarkable 145% year-over-year growth, indicating strong momentum in the company's financial performance. The firm is expected to benefit from reduced research and development expenses, leading to a revised fiscal year 2025 earnings per share (EPS) estimate improvement from $(5.32) to $(2.72). Despite a slight reduction in revenue forecasts for FY25, the positive adjustments to earnings estimates reflect confidence in the company's operational efficiency and prospects in developing therapies for infectious diseases.

Bears say

60 Degrees Pharmaceuticals Inc is experiencing sequential declines in product revenues, which fell to $100,000 owing to supply constraints, raising concerns about the firm's revenue ramp and overall financial stability. Additionally, the company lacks visibility on regulatory approvals for its pipeline products, underscoring potential risks associated with future revenue streams. Furthermore, the possibility of financing-related dilution poses an additional threat to the stock, diminishing outlook for investors.

SXTP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 1 analysts, SXTP has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.